Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Repurchased Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Lisata Therapeutics (LSTA) Divestments (2016 - 2017)

Lisata Therapeutics filings provide 4 years of Divestments readings, the most recent being -$74.9 million for Q4 2017.

For the quarter ending Q4 2017, Divestments fell 347.04% year-over-year to -$74.9 million, compared with a TTM value of -$74.9 million through Sep 2018, down 229.24%, and an annual FY2017 reading of -$189000.0, up 89.2% over the prior year.
Divestments hit -$74.9 million in Q4 2017 for Lisata Therapeutics, down from $4.4 million in the prior quarter.
The five-year high for Divestments was $65.3 million in Q2 2017, with the low at -$74.9 million in Q4 2017.